Our pipeline & IP
EpiAxis is developing a series of products targeting LSD1, PKC theta and PD1/PDL1. Please contact email@example.com to discuss partnering/licensing.
Our intellectual property
Our wholly owned IP is broad and includes strong coverage for our therapeutic portfolio and includes a dominating position for LSD1 inhibitors used in combination with surgery, radiotherapy or chemotherapy or immuno-therapy.